Merck’s (KEYTRUDA in combination with ALIMTA and Pt CT) Receives EU Approval for 1L mNonsq NSCLC with no EGFR or ALK Genomic Tumour

Shots:

• The approval is based on KEYNOTE-189 P-III study, assessing (KEYTRUDA + pemetrexed ALIMTA and Pt CT vs CT alone) administering KEYTRUDA 200 mg, cisplatin/carboplatin, and pemetrexed q3w IV for four cycles followed by KEYTRUDA 200 mg for up to 24 mos and pemetrexed q3w or (PBO + cisplatin/carboplatin and pemetrexed) q3w IV for four cycles followed by pemetrexed q3w
• P-III KEYNOTE-189 study demonstrated: reducing risk of death by 51%; 48% reduction in the risk of progression/death; ORR (48% vs 19%); DOR (11.2 vs 7.8mos)
• EU approval allows marketing of Keytruda (200mg q3w) + combination in Iceland, Lichtenstein, Norway and in 28 EU member states

Click here to read full press release/ article | Ref: Merck | Image: Caixin Global